Cigna initiated with a Buy at UBS. UBS analyst Whit Mayo started with a Buy rating and $185 price target. Cigna has lost a third of its value since announcing the Express Scripts transaction in early 2018 and now trades at eight times estimated 2020 earnings, Mayo tells investors in a research note. The analyst believes the current valuation reflects an “overly harsh and economic unrealistic view.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.